{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"MTD was based on the assessment of dose-limiting toxicity (DLT) during cycle 1 only and was defined as the highest dose at which fewer than one-third of participants in a cohort experience DLT. A DLT was defined as any of the following drug-related toxicities occurring during Cycle 1: Hematologic adverse events (AEs) (Grade 4 hematologic AEs, Grade 3 hematologic AEs with sequelae); Grade 3 nonhematologic AEs; Neuropathy (Grade 2 neuropathy, Grade 1 neuropathy with pain, worsening grade of neuropathy or new symptoms of pain associated with neuropathy); Any other toxicity that, in the judgment of the principal investigator, was a DLT; If a participant cannot receive 75% of the planned dose for any of the 3 agents (missing \\>1 dose of CEP-18770, or \\>5 doses of lenalidomide, or \\>1 dose of dexamethasone \\[either consecutively or separately\\]), due to a drug-related AE, the event was considered a DLT, even if the grade of toxicity was lower than specified DLT determination as described above.","groups":[{"description":"Participants received CEP-18770 Dose A, Dose B or Dose C IV on Days 1, 8, and 15 in each 28-day cycle. In addition, participants received a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"Overall Population"}],"paramType":"NUMBER","populationDescription":"The MTD determination set included all participants who received at least 3 doses of the study drug during the first cycle. In addition, any participant who experienced a drug related DLT during Cycle 1 was considered evaluable regardless of the number of doses received.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (28 days)","title":"Maximum Tolerated Dose of CEP-18770","type":"PRIMARY","unitOfMeasure":"mg/m^2"}